Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
BIODESIX INC (BDSX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 SC 13D/A SCHULER JACK W reports a 32.1% stake in Biodesix, Inc.
08/09/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 SC 13D/A PATIENCE JOHN reports a 7.9% stake in Biodesix, Inc.
08/07/2023 SC 13D/A Kennedy Lawrence T. Jr reports a 22% stake in Biodesix, Inc.
08/07/2023 8-K Quarterly results
Docs: "Biodesix Announces Second Quarter 2023 Results and Highlights Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Second quarter 2023 gross profit margin of 73% versus 64% for the second quarter 2022 and 65% for the first quarter 2023; Revenue continues to track to 2023 full year guidance of $52-55 million; Approximately $27.5 million in common shares sold under a private placement from the Company’s largest investors, Board of Directors members, and Executive Leadership team; Multiple publications and data presentations on the clinical utility and health economic benefits of Core Lung Diagnostics tests; Conference Call and Webcast Today at 4:30 p.m. ET BOULDER, CO, August 7, 2023 –"
07/26/2023 8-K Quarterly results
07/26/2023 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
07/03/2023 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/25/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/11/2023 8-K Quarterly results
Docs: "Biodesix Announces First Quarter 2023 Results and Highlights First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; Conference Call and Webcast Today at 4:30 p.m. ET BOULDER, CO, May 11, 2023 –"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 144 Form 144 - Report of proposed sale of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
03/31/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/21/2023 SC 13G HIRSCHMAN ORIN reports a 7.1% stake in BioDesix, Inc.
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively 2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range represents growth in excess of 60% over 2022 revenues excluding revenues from COVID-19 testing Conference Call and Webcast Today at 8:30 a.m. ET BOULDER, CO, March 6, 2023 –"
02/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/13/2023 SC 13D Kennedy Lawrence T. Jr reports a 19.4% stake in Biodesix, Inc.
12/16/2022 8-K Quarterly results
12/01/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
11/30/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/23/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/23/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/23/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/21/2022 8-K Quarterly results
11/18/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/16/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
10/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Biodesix Announces Preliminary Revenue for Third Quarter 2022 Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Boulder, CO, October 11, 2022"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy